Topotarget increases its share capital by 0.03% as a result of employee warrant exercise

Topotarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen Ø
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com


Copenhagen, Denmark -  April 2010 - TopoTarget (CSE: TOPO) increases its share
capital by DKK nominally 43,030, divided into 43,030 shares of DKK nominally 1,
as a consequence of the exercise of employee warrants. 

The new shares are issued to the warrant holders without pre-emption rights to
Topotarget's existing shareholders or others. The new shares are ordinary
shares without any special rights and are freely transferable instruments. The
shares are eligible for dividends from the time when the capital increase is
registered with the Danish Commerce and Companies Agency. 

The shares are subscribed in cash at a subscription price of DKK 3.20 per share
of DKK 1 nominally in respect of 43,030 shares. The capital increase provides
Topotarget with proceeds of DKK 137,696. 

The warrants exercised were issued in 2009.
 
The capital increase is expected to be registered with the Danish Commerce and
Companies Agency on 12 April 2010, and as soon as possible thereafter the new
shares will be admitted to and listed for trading on the Copenhagen Stock
Exchange. After the capital increase, the company's share capital will make up
DKK 132,652,050 nominally, divided into 132,652,050 shares. 

The capital increase corresponds to 0.03% of Topotarget's existing share
capital. 

Topotarget A/S

For further information, please contact:

Francois Martelet		Direct	+45 39 17 94 99
CEO   				Mobile	+45 31 36 83 41









Background information

About Topotarget 
Topotarget (NASDAQ OMX: TOPO) is an international biotech company headquartered
in Denmark, dedicated to finding ''Answers for Cancer'' and developing improved
cancer therapies. Topotarget currently focuses, in collaboration with Spectrum
Pharmaceuticals, Inc., on the development in pivotal studies of its lead drug
candidate, Belinostat, which has shown proof of concept as monotherapy in
treating haematological malignancies and positive results in solid tumours.
Belinostat can be used in combination with full doses of chemotherapy, and is
in a pivotal trial within PTCL (peripheral T-cell lymphoma). Topotarget's
expertise in translational research is based on utilising its highly predictive
in vivo and in vitro cancer models. Topotarget is directing its efforts on key
cancer targets, including HDACi, NAD+, mTOR, FASLigand and topoisomerase II
inhibitors. The Company's first marketed product, Savene®/Totect®, was approved
by EMEA in 2006 and the FDA in 2007, and is marketed by Topotarget's own sales
force in the US. For more information, please refer to www.topotarget.com. 

Topotarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. Topotarget cautions investors that
there can be no assurance that actual results or business conditions will not
differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
Topotarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks;  uncertainty of additional funding; Topotarget's history of
incurring losses and the uncertainty of achieving profitability; Topotarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against Topotarget's products, processes and
technologies; the ability to protect Topotarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.